FDA’s final guidelines for co-development of investigational drugs for combination use retain the key principles laid out in a 2010 draft document but provide more extensive instruction to companies on how to submit INDs and marketing applications for such products.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?